Retrospective evaluation of premenopausal hormone‐sensitive breast cancer patients treated with adjuvant gonadotropin‐releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study

• DOI: 10.1111/ajco.12685
• Publication Date: 2017-04-21T06:22:50Z
• Authors: Ayşe Demirci; Necati Alkış; Faysal Dane; Ayşe Durnalı; Ömer Kamil Yazıcı; Rashad Rzayev; Serap Kaya; Doğan Yazılıtaş; Mevlüde İnanç; Melike Özçelik; Tülay Akman; Mehmet Ali Kaplan; Yusuf Günaydın; Arife Ulaş; Özlem Sönmez; Saadet Tokluoğlu; Gamze Gököz Doğu; Öznur Bal; Mahmut Gümüş
• Keywords: cancer patient; demography; Adult; Breast Neoplasms/*drug therapy/mortality; Disease-Free Survival; Female; Gonadotropin-Releasing Hormone/pharmacology/*therapeutic use; Humans; Medical Oncology; Middle Aged; Retrospective Studies; Young Adult; retrospective study; gonadorelin associated peptide derivative; Medical Oncology; Turkey (republic); fluorouracil; Gonadotropin-Releasing Hormone; 0302 clinical medicine; middle aged; docetaxel; cancer survival; disease free survival; tamoxifen; breast tumor; adult; adjuvant therapy; hormone sensitivity; Middle Aged; medical oncology; 3. Good health; trastuzumab; female; priority journal; early cancer; cancer grading; oncology; young adult; Female; pharmacy; Adult; overall survival; premenopause; 610; Breast Neoplasms; anthracycline; Article; Disease-Free Survival; multiple cycle treatment; Young Adult; 03 medical and health sciences; breast cancer; follow up; Humans; controlled study; human; survival time; Retrospective Studies; treatment duration; major clinical study; mortality; gonadorelin; aromatase inhibitor; cyclophosphamide

AbstractAimThe goal of this study is to evaluate possible factors affecting the survival of patients treated with gonadotropin‐releasing hormone (GnRH) analogues.MethodsDemographic characteristics, treatment modalities, overall survival (OS) and the possible factors affecting the survival a total of 554 premenopausal breast cancer patients in Turkey evaluated retrospectively.ResultsThe median duration of GnRH analogues use was 22 ± 13.6 (range, 1–87) months. Patients were divided into three groups according to the duration of GNRH analogues use; 4–12 months (Group A), 13–24 months (Group B) and ≥25 months (Group C). Overall, 530 patients were analyzed; 23.2%, 45.8%, 30.9% of the patients were in Group A, B and C, respectively. The median follow‐up duration was 34 ± 30.3 (range, 4–188) months. The OS in patients ≤35 years of age was found to be significantly longer than that of patients >35 years of age in Group B (log rank, P = 0.023). The disease‐free survival of the patients in Group A was significantly shorter than that of patients in Group C (log rank, P = 0.003). The OS of Group A patients was significantly shorter in comparison to that of Group B and Group C patients (log rank, P = 0.000) and the OS of Group B patients was significantly shorter than Group C (log rank, P = 0,000).ConclusionThere is currently no definite data on the optimal duration of GnRH analogues use. One of the important results of this study that will provide an insight to the future studies is the improvement gained in OS by the increase in the duration of GnRH analogues use.